ERBB2 and breast carcinoma: Because of their roles in multiple carcinogenesis pathways, including the cell cycle, angiogenesis, and metastasis, inhibitors targeting HER2, PI3K, AKT, fibroblast growth factor receptors (FGFRs), mTOR, PARP, or vascular endothelial growth factor (VEGF) may be used as therapeutic methods to halt the advancement of breast cancer [7].